AbbVie to buy immune drug developer Landos
About 67% of Cerevel Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Cerevel Therapeutics Holdings suggests that many traders are alarmed regarding Cerevel Therapeutics' prospects. The current market sentiment, together with Cerevel Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Cerevel Therapeutics stock news signals to limit their universe of possible portfolio assets.
Cerevel |
Worth about 138 million upfront, the deal is another example of pharma interest in new drugs for inflammatory conditions like Crohns.
Read at finance.yahoo.com
 |
Cerevel Therapeutics Fundamental Analysis
We analyze Cerevel Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cerevel Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cerevel Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Cerevel Therapeutics is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Cerevel Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cerevel Therapeutics stock to make a market-neutral strategy. Peer analysis of Cerevel Therapeutics could also be used in its relative valuation, which is a method of valuing Cerevel Therapeutics by comparing valuation metrics with similar companies.
Peers
Cerevel Therapeutics Related Equities
| IGMS | IGM Biosciences | 7.47 | ||||
| MLYS | Mineralys Therapeutics, | 5.64 | ||||
| DSGN | Design Therapeutics | 4.67 | ||||
| APLS | Apellis Pharmaceuticals | 4.39 | ||||
| TVTX | Travere Therapeutics | 4.04 | ||||
| GPCR | Structure Therapeutics | 2.38 | ||||
| BPMC | Blueprint Medicines | 1.29 | ||||
| SWTX | SpringWorks Therapeutics | 0.94 | ||||
| STOK | Stoke Therapeutics | 0.33 | ||||
| DAWN | Day One | 0.65 | ||||
| IKNA | Ikena Oncology | 1.16 | ||||
| GLUE | Monte Rosa | 1.35 | ||||
| TERN | Terns Pharmaceuticals | 1.44 | ||||
| HOWL | Werewolf Therapeutics | 2.00 | ||||
| CGEM | Cullinan Oncology | 2.08 | ||||
| NUVL | Nuvalent | 2.49 | ||||
| RNA | Avidity Biosciences | 4.02 | ||||
| VTYX | Ventyx Biosciences | 5.97 | ||||
| RVMD | Revolution Medicines | 10.46 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in Cerevel Stock
If you are still planning to invest in Cerevel Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cerevel Therapeutics' history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |